Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations (TOP)

This is a phase III clinical trial aimed to compare the efficacy and safety of Osimertinib monotherapy and combination of Osimertinib, pemetrexed and carboplatin in untreated patients with advanced non-small cell lung cancer with concurrent EGFR and TP53 mutation.

Study Overview

• Status: Not yet recruiting
• Conditions: Non-small Cell Carcinoma; EGFR Gene Mutation
• Intervention / Treatment: Drug: Osimertinib 80 MG [Tagrisso]; Drug: Pemetrexed 500 MG Injection; Drug: Carboplatin

Detailed Description

This is a multicenter, randomized, open label, phase III study comparing the progression free survival, overall survival, response rate, toxicity, quality of life between Osimertinib monotherapy and combination of osimertinib, pemetrexed, carboplatin in first-line treatment of advanced non-small cell lung cancer patients with concurrent EGFR and TP53 mutation. Besides, the association between other genetic mutations and efficacy will also be analyzed as exploratory endpoint. Eligible patients will be randomized to receive either osimertinib or osimertinib combined with pemetrexed and carboplatin in a 1:1 ratio.

• Study Type: Interventional
• Enrollment (Anticipated): 291
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Department of Medical Oncology,Cancer Center of Sun Yat-Sen University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures;
2. Male or female, aged at least 18 years;
3. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1;
4. Life expectancy of at least 3 months;
5. Histologically or cytologically confirmed stage IV or recurrent non-squamous non-small cell lung carcinoma with activating EGFR mutations (exon 19 deletion or exon 21 L858R point mutation) and concurrent TP53 mutations;
6. No prior palliative chemotherapy, or palliative biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VGEF) inhibitors) or immunological therapy （Previous adjuvant chemotherapy is permitted if treatment was completed more than 6 months before day 1. Palliative radiotherapy to a metastatic site is permitted, but palliative wide field radiotherapy to the lung must be completed at least 4 weeks before day 1 with no persistence of any radiotherapy-related toxicity;

7. Adequate organ function, including the following:

   Adequate bone marrow reserve: absolute neutrophil (segmented and bands) counts (ANC) ≥ 1.5X109/L, Platelets ≥100X109/L, HGB ≥90g/L; Hepatic: bilirubin ≤ 1.5 times the upper limit of normal (xULN), alanine aminotransferase (ALT) & aspartate aminotransferase (AST) ≤ 3.0 times the ULN if no demonstrable liver metastases (AST, ALT ≤ 5 XULN is acceptable if liver has tumor involvement); Serum Creatinine ≤ 1.5 times the ULN and Creatitne Clearance ≥ 50 ml/min;

8. At least one measurable lesion (according to RECIST1.1). Baseline measurable lesions were defined as: non-lymph node lesions with longest diameter ≥ 10 mm or lymph node lesions with short diameter ≥ 15 mm measured by CT or MRI. No previous regional treatment such as radiotherapy should be performed to treat Measurable lesions. Tumor tissue previous received radiotherapy should not be biopsied during the screening period. If there is only one measurable lesion, biopsy of this lesion if permitted but the baseline imaging examination of this lesion must be performed at least 14 days after the biopsy.

Exclusion Criteria:

1. Known severe hypersensitivity to Osimertinib, carboplatin, pemetrexed or any of the excipients of the above-mentioned product. Known severe hypersensitivity to pre-medications required for treatment with carboplatin / pemetrexed doublet chemotherapy;
2. History or presence of any other malignancy with the exception of cancer in situ which has undergone radical resection and has not relapsed within 5 years (eg. basal cell carcinoma or cervical cancer);
3. Past medical history of interstitial lung disease, drug induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease;
4. Any unresolved chronic toxicity ≥ CTCAE grade 2 from previous anticancer therapy;
5. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);
6. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study;
7. Pregnancy or breast feeding;
8. Use of unapproved drugs or research drugs within 30 days before the start of the study;
9. Symptomatic brain metastases.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: osimertinib monotherapy; osimertinib 80 mg po qd.	Drug: Osimertinib 80 MG [Tagrisso]; osimertinib 80 mg po qd until disease progression
Experimental: combination of osimertinib and chemotherapy; osimertinib 80 mg po qd plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance osimertinib and pemetrexed until disease progression	Drug: Osimertinib 80 MG [Tagrisso]; osimertinib 80 mg po qd until disease progression; Drug: Pemetrexed 500 MG Injection; pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression; Drug: Carboplatin; carboplatin area under curve 5 intravenously every 3 weeks for four cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
progression free survival	defined as the time from randomization to the date of first documentation of from date of randomization until the date of first documented progression or date of death from any cause, whichever came first	assessed up to 36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
overall survival	from date of randomization until the date of death from any cause	assessed up to 60 months
percentage of participants with objective response (partial response [PR] plus complete response [CR])	assessed using RECIST v.1.1	up to 36 months
Incidence and severity of adverse events (AEs)	Overall incidence of AEs; the incidence of grade 3 or above AEs; the incidence of severe adverse events (SAE); the incidence of drug-related AEs; the incidence of AEs resulting in permanent withdrawal of drugs; the incidence of AEs leading to dose adjustment	through study completion, an average of 60 months
Change from baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score.	The EORTC QLQ-C30 consists of 30 questions that comprise aspects of participant's functioning assessment (physical, emotional, role, cognitive, and social); symptom scales (fatigue; nausea, vomiting, and pain; the global health/quality of life [QoL]); and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), within a recall period of "the past week." Most questions used a 4-point scale (1=Not at all to 4=Very much; two questions used a 7-point scale (1=Very poor to 7=Excellent). Scores were averaged and transformed to a 0-100 scale; a higher score for Global Qol/functional scales=better level of functioning; a higher score for symptom scale=greater degree of symptoms.	up to 36 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between subtypes of EGFR mutations, TP53 mutations and other potential predictive biomarkers and response to treatment	These biomarkers will be assessed by next generation sequencing of tumor tissue or peripheral blood	up to 36 weeks

Collaborators and Investigators

• Sponsor: Li Zhang, MD

Study record dates

Study Major Dates

• Study Start (Anticipated): January 4, 2021
• Primary Completion (Anticipated): September 30, 2022
• Study Completion (Anticipated): December 30, 2023

Study Registration Dates

• First Submitted: December 20, 2020
• First Submitted That Met QC Criteria: January 3, 2021
• First Posted (Actual): January 5, 2021

Study Record Updates

• Last Update Posted (Actual): January 5, 2021
• Last Update Submitted That Met QC Criteria: January 3, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Folic Acid Antagonists; Carboplatin; Osimertinib; Pemetrexed
• Other Study ID Numbers: IIT-2470

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes